You can buy or sell ADMP and other stocks, options, ETFs, and crypto commission-free!
Adamis Pharmaceuticals Corporation Common Stock, also called Adamis Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development and sales of pharmaceutical, specialty biopharmaceutical and other drug products. It offers Symjepi product for allergy, respiratory, opioid overdose, and erectile dysfunction (ED), markets. Read More The company was founded in June 2006 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Seeking AlphaMay 10
Adamis Pharmaceuticals' CEO Dennis Carlo on Q1 2019 Results - Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Dennis Carlo – President and Chief Executive Officer Rob Hopkins – Chief Financial Officer Ronald Moss – Chief Medical Officer Dave Marguglio – Chief Business Officer Conference Call Participants Elliot Wilbur – Raymond James Jason McCarthy – Maxim Group Jason Kolbert – Dawson James Operator Good day and welcome to the Adamis Pharmaceuticals Corp First Quarter 2019...
Yahoo FinanceMay 7
Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including respiratory disease and allergy, announced today that it will host an investor conference call on Thursday, May 9, 2019 at 2:00 pm Pacific Time to discuss its financial and operating results for the first quarter of 2019 as well as provide an update on business developments and activities.
Yahoo FinanceMay 2
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Adamis Pharmaceuticals (ADMP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
-$0.16 per share
-$0.19 per share